ReviewJournal of pharmaceutical analysis2026
Extraction and determination of sartans: Recent advances and analytical perspectives.
Review in Journal of pharmaceutical analysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sartans are essential antihypertensive drugs requiring reliable analytical methods for quality and efficacy monitoring. This review provides a comprehensive overview of recent analytical advances for sartans, focusing on pretreatment and detection methods. For sample preparation, conventional methods like protein precipitation, liquid-liquid extraction (LLE) and solid-phase extraction (SPE) have been optimized through the adoption of green solvents and automation. Emerging novel microextraction techniques including liquid phase microextraction and solid phase microextraction, in combination with advanced materials improve selectivity, especially for complex biological matrices. In the realm of detection, liquid chromatography-mass spectrometry (LC-MS) remains dominant, with high-resolution mass spectrometry (HRMS) (time-of-flight, orbitrap) enabling trace-level quantification and structural identification, outperforming traditional low-resolution mass spectrometry (LRMS). Emerging sensors offer rapid screening but lack MS-level multiplexing capability. The choice of methods should be based on sample complexity and analytical needs: biological samples benefit from microextraction-HRMS combinations, whereas pharmaceutical analysis may use simpler SPE-LC/MS workflows. Future directions should emphasize miniaturized, automated, and eco-friendly approaches to enhance throughput while reducing environmental impact. This review serves as a practical guide for selecting suitable strategies for the analysis of sartans across diverse analytical scenarios.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.